It could also help it keep pace with rival drugs in the SGLT2 inhibitor class as competition gets more intense. Last year, Jardiance achieved encouraging results in the EMPA-REG OUTCOME trial ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Big Pharma is again raising the prices for key medications that could save the lives of millions in Georgia and there are ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...